Associated Genetic Biomarkers
Associated Diseases
Associated Pathways

Overview

Location [1]
10q26.13
Pathways
Receptor tyrosine kinase/growth factor signaling, Kinase fusions
Protein [2]
Fibroblast growth factor receptor 2
Synonyms [1]
KGFR, BFR-1, K-SAM, CEK3, CD332, BEK, BBDS, JWS, CFD1, ECT1, TK25, TK14

FGFR2 (fibroblast growth factor receptor 2 gene) encodes the fibroblast growth factor receptor 2 protein, a receptor tyrosine kinase. FGFR2 and other FGFR TKs play crucial roles in development and have been shown in cancers to be deregulated by amplification, point mutation, or translocation (PMID: 20094046). Amplification or activation of FGFR2 has been reported in breast cancer and gastric cancer (PMID: 22731805). FGFR2 mutations have been observed in endometrial cancer and breast cancer (PMID: 18552176; PMID: 22731805; PMID: 23527311).

 

FGFR2 is altered in 1.77% of all cancers with endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, colon adenocarcinoma, lung adenocarcinoma, and cutaneous melanoma having the greatest prevalence of alterations [3].

FGFR2 GENIE Cases - Top Diseases

The most common alterations in FGFR2 are FGFR2 Mutation (1.99%), FGFR2 Amplification (0.34%), FGFR2 S252W (0.17%), FGFR2 N549K (0.09%), and FGFR2 C382R (0.09%) [3].

FGFR2 GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of FGFR2 in Diseases

Cholangiocarcinoma +

Malignant Solid Tumor +

Urothelial Carcinoma +

Non-Small Cell Lung Carcinoma +

Breast Carcinoma +

Gastric Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Intrahepatic Cholangiocarcinoma +

Bladder Carcinoma +

Cancer +

Multiple Myeloma +

Endometrial Carcinoma +

Gastric Adenocarcinoma +

Colorectal Carcinoma +

Esophageal Carcinoma +

Squamous Cell Lung Carcinoma +

Pancreatic Carcinoma +

Melanoma +

Non-Hodgkin Lymphoma +

Glioblastoma +

Ovarian Carcinoma +

Sarcoma +

Anaplastic Astrocytoma +

Head And Neck Carcinoma +

Head And Neck Squamous Cell Carcinoma +

Endometrioid Adenocarcinoma +

Malignant Uterine Neoplasm +

Bile Duct Carcinoma +

Transitional Cell Carcinoma +

Oropharyngeal Carcinoma +

Oropharyngeal Squamous Cell Carcinoma +

Oral Cavity Squamous Cell Carcinoma +

Cervical Carcinoma +

Malignant Hepatobiliary Neoplasm +

Hepatobiliary Neoplasm +

Malignant Salivary Gland Neoplasm +

Lung Carcinoma +

Invasive Breast Carcinoma +

Lymphoma +

Glioma +

Lymphocytic Neoplasm +

Pancreatic Adenocarcinoma +

Anaplastic Oligodendroglioma +

B-Cell Non-Hodgkin Lymphoma +

Bladder Papillary Urothelial Carcinoma +

Bronchogenic Carcinoma +

Esophageal Squamous Cell Carcinoma +

Extrahepatic Cholangiocarcinoma +

Gallbladder Carcinoma +

Gastrointestinal Stromal Tumor +

Histiocytic And Dendritic Cell Neoplasm +

Hypopharyngeal Squamous Cell Carcinoma +

Laryngeal Squamous Cell Carcinoma +

Lip And Oral Cavity Carcinoma +

Malignant Laryngeal Neoplasm +

Myeloid Neoplasm +

Myeloproliferative Neoplasm +

Nasal Cavity And Paranasal Sinus Carcinoma +

Nasopharyngeal Carcinoma +

Oral Cavity Carcinoma +

Perihilar Intrahepatic Cholangiocarcinoma +

Small Cell Lung Carcinoma +

Stage 0is Bladder Urothelial Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.